NEURODEGENERATIVE DISEASES

This study tested an experimental drug called XPro1595 in 208 people with early Alzheimer's disease who also had signs of brain inflammation. The goal was to see if the drug could improve memory, thinking, and daily function compared to a placebo over 24 weeks. Researchers also c…

This completed Phase 2b/3 trial tested the drug AMX0035 in 139 people with progressive supranuclear palsy (PSP), a rare brain disease that causes problems with balance, movement, and thinking. The study compared the drug to a placebo to see if it could slow the disease. The resul…

This study is a follow-up to an earlier trial, testing the long-term safety and effects of a drug called AOC 1001 in adults with myotonic dystrophy type 1 (DM1), a genetic muscle disease. 37 participants who completed the first study received multiple doses of AOC 1001 by IV infu…

This study tested whether ultrasound of the nerves can help diagnose CANVAS, a rare genetic disorder that causes balance problems, nerve damage, and dizziness. Researchers measured nerve size in 35 people with confirmed CANVAS and compared them to healthy individuals. The goal wa…

Researchers tested an artificial intelligence program that analyzes retinal images to diagnose several nerve and brain conditions, such as optic neuropathy and brain tumors. The study used data from 693 patients with confirmed diagnoses. The goal is to create a fast triage tool f…

This completed study created the first international database of Datscan imaging values from 300 patients. The goal was to help doctors better diagnose Parkinson's disease and other neurodegenerative conditions by comparing brain scan results. Researchers hope this database will …

This study tested whether home automation and remote monitoring can help elderly people (65+) with multiple chronic conditions live safely at home. Over 500 participants had their homes equipped with sensors that tracked health signs and sent alerts to doctors. The main goal was …

This study tested whether a daily NAD+ supplement can improve thinking and reduce inflammation in healthy women aged 40 to 80. Participants took either NAD+ or a placebo for 4 weeks and completed computer tests and blood draws. The goal was to see if NAD+ affects memory, attentio…